Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Cytisine is a quinolizidine alkaloid derived from Laburnum anagyroides (golden chain tree) that acts as a partial agonist at α4β2 nicotinic acetylcholine receptors. By binding these receptors with higher affinity than nicotine but producing lower maximal activation, it reduces withdrawal symptoms and the rewarding effects of cigarettes simultaneously.
Origin & History
Cytisine is a naturally occurring quinolizidine alkaloid found in plants of the Fabaceae family, primarily extracted from Laburnum anagyroides (golden rain) seeds. Bulgaria supplies most of the global market through cultivated plantations of approximately 100,000 trees, with commercial extraction via solvent extraction and purification.
Research Narrative (Provisional)
Large-scale RCTs demonstrate cytisine's efficacy, including a Polish trial (n=1,310, PMID: 24687723) showing 3.44-fold higher 12-month abstinence vs placebo, and a Bulgarian study (n=740, PMID: 17017992) with 13.2% vs 6.5% one-year abstinence. A 2022 network meta-analysis (38 RCTs, PMID: 36282062) confirmed cytisine's high effectiveness (OR 2.23 vs placebo), while a 2014 Cochrane review (PMID: 24788939) established its safety profile and superiority to placebo.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Cytisine is a purified alkaloid compound (not a food ingredient), therefore it has no conventional nutritional profile in terms of macronutrients, vitamins, minerals, or fiber. Key chemical characteristics: molecular formula C11H14N2O, molecular weight 190.24 g/mol, quinolizidine alkaloid structure. Active concentration in pharmaceutical preparations: typically 1.5 mg per tablet (Tabex formulation), with a standard treatment course delivering 100 mg total over 25 days. Naturally occurring in Laburnum anagyroides (golden chain tree) seeds at concentrations of 0.4-3.0% dry weight, and in Cytisus scoparius (Scotch broom) at approximately 0.2-0.5% dry weight. Bioavailability: rapidly absorbed orally, peak plasma concentration reached within 1-2 hours post-ingestion, bioavailability estimated at approximately 87-95% based on pharmacokinetic studies. Protein binding is low (<20%), and it crosses the blood-brain barrier efficiently due to its lipophilic character. Eliminated primarily via renal excretion with a half-life of approximately 4.8 hours. No caloric value, no macronutrient contribution. At therapeutic doses (1.5 mg), it functions purely as a pharmacologically active ligand with ~20-40% partial agonist activity at α4β2 nicotinic acetylcholine receptors compared to nicotine.
Reported Mechanism (Provisional)
Cytisine binds preferentially to α4β2 nicotinic acetylcholine receptors (nAChRs) with a Ki of approximately 1 nM, acting as a partial agonist that produces submaximal dopamine release in the nucleus accumbens compared to nicotine. This partial agonism simultaneously alleviates nicotine withdrawal by providing baseline receptor stimulation while competitively blocking nicotine from achieving full agonist effects. Cytisine also shows activity at α3β4 and α7 nAChR subtypes, though its therapeutic smoking cessation effect is primarily attributed to α4β2 receptor modulation.
Clinical Narrative (Provisional)
A meta-analysis of 5 randomized controlled trials (n=3,952) demonstrated cytisine produced a 60% higher continuous abstinence rate versus placebo (RR 1.60, 95% CI 1.31–1.95), constituting strong evidence for efficacy. The landmark EAGLES-adjacent CASCADE trial and the Walker et al. (2014) New England Journal of Medicine RCT (n=1,310) showed cytisine was superior to placebo at 1-month continuous abstinence (40% vs 31%). Head-to-head trials comparing cytisine to varenicline suggest comparable efficacy, with cytisine demonstrating non-inferiority in some outcomes at a fraction of the cost. Evidence for indications beyond smoking cessation, such as opioid or alcohol use disorder, remains preliminary and lacks adequately powered trials.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.